Prognostication of clinical outcomes in diabetes mellitus: Emerging role of cardiac biomarkers

• Published in: Diabetes & metabolic syndrome clinical research & reviews Vol. 13; no. 2; pp. 995 - 1003
• Main Author: Berezin, Alexander E.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01-03-2019
• Subjects: Biomarkers - blood; Cardiac biomarkers; Cardiovascular Diseases - blood; Cardiovascular Diseases - epidemiology; Cardiovascular risk; Diabetes Mellitus, Type 2 - physiopathology; Humans; Incidence; Mortality; Prediction; Prognosis; Risk Assessment - methods; Risk Factors; Type 2 diabetes mellitus; Ukraine - epidemiology; Ukraine; Type 2 diabetes mellitus; Cardiac biomarkers; Mortality; Cardiovascular risk; Prediction
• ISSN: 1871-4021; 1878-0334
• DOI: 10.1016/j.dsx.2019.01.018

Type 2 diabetes mellitus (T2DM) remains substantial health problem and one of the most prevalent metabolic diseases worldwide. The impact of T2DM on CV mortality and morbidity is embedded through a nature evolution of the disease and is modulated by numerous risk factors, such as hypertension, obesity, dyslipidemia. There is large body of evidence regarding use of the cardiac biomarkers to risk stratification at higher CV risk individuals who belongs to general population and cohort with established CV disease. Although T2DM patients have higher incidence of cardiac and vascular complications than the general population, whether cardiac biomarkers would be effective to risk stratification of the T2DM is not fully understood. The aim of the review is to summarize our knowledge regarding clinical implementation of cardiac biomarkers in risk assessment for T2DM patients. The role of natriuretic peptides, soluble ST2, galectin-3, growth differentiation factor-15, and cardiac troponins are widely discussed.